Drug · CHEMBL1908373
ONAPRISTONE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ONAPRISTONE. Drugs and targets, record CHEMBL1908373. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1908373
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Phase 2, for 4 of its 5 diseases, from ClinicalTrials.gov and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PGR | Progesterone receptor | Progesterone receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/5241 |
Source ChEMBL
Diseases5
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Phase 2 | ClinicalTrials.gov and TTD | 6 | 5 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| endometrial cancer | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0011962 |
| endometrial carcinoma | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0002447 |
| granulosa cell tumor | Phase 2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006036 |
| prostate cancer | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
Source Open Targets
Trials9
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03909152 | A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone | Phase 2 | 34 | 2025-07-28 | onapristone | Its name | ClinicalTrials.gov |
| NCT04738292 | Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) | Phase 2 | 11 | 2024-05-03 | onapristone | Its name | ClinicalTrials.gov |
| NCT02049190 | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | Phase 1/2 | 75 | onapristone | Its name | ClinicalTrials.gov | |
| NCT02052128 | Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers | Phase 1/2 | 60 | onapristone | Its name | ClinicalTrials.gov | |
| NCT04719273 | Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer | Phase 2 | 14 | onapristone | Its name | ClinicalTrials.gov | |
| NCT04142892 | Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer | Early phase 1 | 10 | onapristone | Its name | ClinicalTrials.gov | |
| NCT05618613 | Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | Phase 1/2 | 4 | onapristone | Its name | ClinicalTrials.gov | |
| NCT04872608 | A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer | Phase 1 | 0 | onapristone | Its name | ClinicalTrials.gov | |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | Phase 1/2 | 0 | onapristone | Its name | ClinicalTrials.gov |
Comparisons in its trials0
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
None in this release.
Papers from its trials2
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908373
GET https://conductscience.org/api/drugs/v1/CHEMBL1908373/targets